JP2016501839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501839A5 JP2016501839A5 JP2015539954A JP2015539954A JP2016501839A5 JP 2016501839 A5 JP2016501839 A5 JP 2016501839A5 JP 2015539954 A JP2015539954 A JP 2015539954A JP 2015539954 A JP2015539954 A JP 2015539954A JP 2016501839 A5 JP2016501839 A5 JP 2016501839A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- antibody
- conjugate
- cytolytic
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001461 cytolytic effect Effects 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 150000008574 D-amino acids Chemical class 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000008575 L-amino acids Chemical class 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229940127121 immunoconjugate Drugs 0.000 claims 3
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 102000008238 LHRH Receptors Human genes 0.000 claims 2
- 108010021290 LHRH Receptors Proteins 0.000 claims 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720257P | 2012-10-30 | 2012-10-30 | |
| US61/720,257 | 2012-10-30 | ||
| PCT/US2013/067621 WO2014070957A1 (en) | 2012-10-30 | 2013-10-30 | Antibody/drug conjugates and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501839A JP2016501839A (ja) | 2016-01-21 |
| JP2016501839A5 true JP2016501839A5 (OSRAM) | 2016-12-15 |
| JP6559066B2 JP6559066B2 (ja) | 2019-08-14 |
Family
ID=50622572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539954A Expired - Fee Related JP6559066B2 (ja) | 2012-10-30 | 2013-10-30 | 抗体／薬剤結合体及び使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9492563B2 (OSRAM) |
| EP (2) | EP4035685A1 (OSRAM) |
| JP (1) | JP6559066B2 (OSRAM) |
| KR (2) | KR20210090298A (OSRAM) |
| CN (1) | CN105121472A (OSRAM) |
| AU (2) | AU2013337926B2 (OSRAM) |
| BR (1) | BR112015009752A2 (OSRAM) |
| CA (1) | CA2889475A1 (OSRAM) |
| DK (1) | DK2914633T3 (OSRAM) |
| IL (1) | IL238323B2 (OSRAM) |
| WO (1) | WO2014070957A1 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| AU2011250970B2 (en) | 2010-05-10 | 2016-12-15 | Sinica, Academia | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| EP2885311B1 (en) | 2012-08-18 | 2020-01-01 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| CA2883168A1 (en) | 2012-08-21 | 2014-02-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
| KR20210090298A (ko) | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| KR102298172B1 (ko) | 2013-09-06 | 2021-09-06 | 아카데미아 시니카 | 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화 |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
| TWI797430B (zh) | 2014-03-27 | 2023-04-01 | 中央研究院 | 反應性標記化合物及其用途 |
| US10005847B2 (en) | 2014-05-27 | 2018-06-26 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
| AU2015267052A1 (en) | 2014-05-27 | 2016-12-15 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR20240096599A (ko) * | 2014-05-27 | 2024-06-26 | 아카데미아 시니카 | 항-ｃｄ20 글리코항체 및 이의 용도 |
| JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗ＴＮＦα糖操作抗体群およびその使用 |
| CN107001404B (zh) | 2014-09-08 | 2021-06-29 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
| MX2017003014A (es) * | 2014-09-12 | 2017-05-30 | Biogen Ma Inc | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. |
| JP6724009B2 (ja) * | 2014-12-08 | 2020-07-15 | アメリカ合衆国 | 抗ｃｄ７０キメラ抗原受容体 |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| TWI736523B (zh) | 2015-01-24 | 2021-08-21 | 中央研究院 | 新穎聚醣結合物及其使用方法 |
| CN107921146A (zh) * | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc) |
| US11197934B2 (en) * | 2015-09-17 | 2021-12-14 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| BR112018009129A2 (pt) | 2015-11-04 | 2019-02-26 | J. PRICEMAN Saul | receptores de antígeno quimérico que visam her2 |
| AU2017213661B2 (en) | 2016-02-05 | 2022-06-02 | City Of Hope | Administration of engineered T cells for treatment of cancers in the central nervous system |
| CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
| EP3496736A4 (en) * | 2016-08-03 | 2020-05-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 targeted therapeutics |
| CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
| AU2017316663B2 (en) | 2016-08-22 | 2024-02-22 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
| US20230182041A1 (en) * | 2018-04-25 | 2023-06-15 | Medimmune, Llc | Purification of antibodies |
| US20220323619A1 (en) * | 2019-07-02 | 2022-10-13 | Telix International Pty Ltd | Antibodies for binding psma with reduced affinity for the neonatal fc receptor |
| CN111100204B (zh) * | 2019-11-26 | 2022-03-11 | 山东立菲生物产业有限公司 | 靶向cd20的抗体、其制备方法和应用 |
| JP2023512084A (ja) * | 2020-01-31 | 2023-03-23 | シージェン インコーポレイテッド | 抗ｃｄ３０抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用 |
| WO2021195553A1 (en) * | 2020-03-26 | 2021-09-30 | Esperance Pharmaceuticals, Inc | Lytic domain fusion constructs, checkpoint inhibitors, and methods of making and using same |
| US11782685B2 (en) | 2020-06-17 | 2023-10-10 | Bank Of America Corporation | Software code vectorization converter |
| US11573775B2 (en) | 2020-06-17 | 2023-02-07 | Bank Of America Corporation | Software code converter for resolving redundancy during code development |
| US11347500B2 (en) | 2020-06-17 | 2022-05-31 | Bank Of America Corporation | Software code converter for resolving conflicts during code development |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| CN113326087B (zh) * | 2021-05-19 | 2023-01-24 | 翱捷科技股份有限公司 | 一种lvgl上的中文字库处理方法及装置 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023133509A2 (en) * | 2022-01-08 | 2023-07-13 | Carogen Corporation | Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection |
| WO2024040024A1 (en) * | 2022-08-15 | 2024-02-22 | Navrogen, Inc. | Fc-ENGINEERED MONOCLONAL ANTIBODIES REFRACTORY TO TUMOR IMMUNOSUPPRESSIVE ICAM-1/CD54 |
| CN116514998B (zh) * | 2023-05-12 | 2023-09-15 | 再少年(北京)生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用 |
| CN116593716B (zh) * | 2023-07-11 | 2023-10-13 | 军科正源（北京）药物研究有限责任公司 | 检测抗PEG-rhGH中和抗体的方法 |
| WO2025131119A1 (en) * | 2023-12-22 | 2025-06-26 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
| WO2025167838A1 (en) * | 2024-02-08 | 2025-08-14 | Suzhou Bioreinno Biotechnology Limited Company | Antibodies, antibody-drug conjugates, and producing methods thereof |
| CN119331056B (zh) * | 2024-09-25 | 2025-07-22 | 青岛大学 | 一种[Tyr3]Octreotate-D-构型溶瘤肽缀合物及其荧光探针的制备方法和应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| CA1327311C (en) | 1987-07-06 | 1994-03-01 | Jesse M. Jaynes | Therapeutic antimicrobial polypeptides, their use and methods for preparation |
| KR970006154B1 (ko) | 1987-07-06 | 1997-04-24 | 루이지아나 스테이트 유니버시티 아그리컬춰럴 앤드 메카니칼 컬리지 | 용해성 펩티드에 의한 진핵 병원체와 신생물의 억제 및 섬유아세포와 임파구의 자극 |
| US5861478A (en) | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
| EP0448650A4 (en) | 1989-02-01 | 1992-05-13 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
| US5459237A (en) | 1990-02-08 | 1995-10-17 | Magainin Pharmaceuticals Inc. | Peptide compositions and uses therefor |
| US5792831A (en) | 1990-02-08 | 1998-08-11 | Magainin Pharmaceuticals Inc. | Analogues of magainin peptides containing D-amino acids |
| EP0514464A4 (en) | 1990-02-08 | 1993-04-28 | Magainin Sciences, Inc. | Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| WO1992022317A1 (en) | 1991-06-12 | 1992-12-23 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides having c-terminal substitutions |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994000136A1 (en) | 1992-06-30 | 1994-01-06 | Oncologix, Inc. | A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING |
| JPH07501820A (ja) | 1991-12-09 | 1995-02-23 | マゲイニン ファーマス−ティカルズ インコーポレーテッド | 生物活性ペプチドおよびキレート剤による組成物および治療法 |
| WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| JPH08500818A (ja) | 1992-06-01 | 1996-01-30 | マガイニン ファーマシューティカルズ，インコーポレーテッド | Ｎ末端置換を有する生物活性ペプチド |
| US6348445B1 (en) | 1992-06-01 | 2002-02-19 | Magainin Pharmaceuticals, Inc. | Biologically active peptides with reduced toxicity in animals and a method for preparing same |
| WO1994005313A1 (en) | 1992-08-31 | 1994-03-17 | Magainin Pharmaceuticals Inc. | Treatment of gynecological malignancies with biologically active peptides |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| JPH08507749A (ja) | 1992-12-03 | 1996-08-20 | マガイニン ファーマシューティカルズ，インク． | 皮膚悪性疾患の生物学的活性を有するペプチドによる治療 |
| EP0672053A1 (en) | 1992-12-07 | 1995-09-20 | Magainin Pharmaceuticals Inc. | Treatment of septic shock with conjugated biologically active peptides |
| AU6251594A (en) | 1993-02-26 | 1994-09-14 | Magainin Pharmaceuticals, Inc. | Treatment of cancerous growths with biologically active peptides and protease inhibitors |
| WO1994025616A1 (en) | 1993-04-28 | 1994-11-10 | Worcester Foundation For Experimental Biology | Cell-targeted lytic pore-forming agents |
| US5955573A (en) | 1993-06-04 | 1999-09-21 | Demegen, Inc. | Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same |
| US5968904A (en) | 1993-06-04 | 1999-10-19 | Demegen, Inc. | Modified arginine containing lytic peptides and method of making the same by glyoxylation |
| US5561107A (en) | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
| US5773413A (en) | 1993-06-04 | 1998-06-30 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasias, and lytic peptides therefor |
| AU7050294A (en) | 1993-06-04 | 1995-01-03 | Demeter Biotechnologies, Ltd. | Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides |
| AU1086595A (en) | 1993-11-08 | 1995-05-29 | Demeter Biotechnologies, Ltd. | Methylated lysine-rich lytic peptides and method of making same by reductive alkylation |
| AU7353494A (en) | 1993-11-12 | 1995-05-29 | Case Western Reserve University | Episomal expression vector for human gene therapy |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5789542A (en) | 1994-04-22 | 1998-08-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Amphipathic peptides |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| IL114697A0 (en) | 1994-07-22 | 1995-11-27 | Demeter Biotech Ltd | Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えｄｎａウイルスおよびその製造方法 |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| AUPN861496A0 (en) * | 1996-03-13 | 1996-04-04 | Commonwealth Scientific And Industrial Research Organisation | Lytic peptides |
| US5712379A (en) * | 1996-06-07 | 1998-01-27 | California Institute Of Technology | Method and compositions for controlling gene expression |
| EP0932413A1 (en) | 1996-10-04 | 1999-08-04 | Demegen, Inc. | Method for treatment of immunodeficiency virus infection |
| US6566334B1 (en) | 1997-02-06 | 2003-05-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Short amphipathic peptides with activity against bacteria and intracellular pathogens |
| AU6587998A (en) | 1997-03-27 | 1998-10-20 | Demeter Biotechnologies, Ltd. | Ligand/lytic peptide compositions and methods of use |
| US6635740B1 (en) | 1997-03-27 | 2003-10-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Ligand/lytic peptide compositions and methods of use |
| CA2294518A1 (en) | 1997-07-15 | 1999-01-28 | Magainin Pharmaceuticals Inc. | Biologically active peptides with reduced toxicity in animals and a method for preparing same |
| US6680058B1 (en) | 1997-09-03 | 2004-01-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for contraception in or sterilization of mammals |
| US6461813B2 (en) | 1998-09-21 | 2002-10-08 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in cell cycle regulation |
| US6656906B1 (en) | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| AU2495200A (en) | 1999-03-08 | 2000-09-28 | Genentech Inc. | Compositions and methods for the treatment of tumor |
| GB0005702D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Method |
| EP1214086A2 (en) | 1999-09-23 | 2002-06-19 | Zentaris AG | Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| MXPA02008870A (es) | 2000-03-14 | 2003-06-24 | Zentaris Ag | Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos. |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6875744B2 (en) | 2001-03-28 | 2005-04-05 | Helix Biomedix, Inc. | Short bioactive peptides |
| DK1443966T3 (da) | 2001-11-15 | 2007-05-21 | Pantarhei Bioscience Bv | Fremgangsmåde til forebyggelse eller behandling af benigne gynækologiske lidelser |
| ES2401428T3 (es) | 2002-04-10 | 2013-04-19 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
| WO2003089455A2 (en) | 2002-04-22 | 2003-10-30 | Dow Global Technologies Inc. | Low-cost production of peptides |
| RS52966B (sr) | 2002-09-27 | 2014-02-28 | Zentaris Gmbh | Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje |
| WO2004035607A2 (en) * | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7091185B2 (en) | 2003-02-24 | 2006-08-15 | Dow Global Technologies Inc. | Periodic antimicrobial peptides |
| US20040167919A1 (en) | 2003-02-24 | 2004-08-26 | David Sterling | Methods for selectable display of parts of a document on a computer monitor |
| EP1599499A2 (en) | 2003-02-24 | 2005-11-30 | Dow Global Technologies Inc. | Periodic antimicrobial peptides |
| GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
| NO20031818D0 (no) | 2003-04-23 | 2003-04-23 | Uni I Tromsoe | Fremgangsmåte av bioaktiv peptid forberedelse |
| GB0320806D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| EP1740946B1 (en) * | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| AU2005287404B2 (en) | 2004-07-22 | 2009-05-07 | Genentech, Inc. | HER2 antibody composition |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GB0506759D0 (en) | 2005-04-02 | 2005-05-11 | Medical Res Council | Combination treatment methods |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| US20090061006A1 (en) | 2006-03-31 | 2009-03-05 | Carola Leuschner | Layered Nanoparticles for Sustained Release of Small Molecules |
| EP2054061A4 (en) * | 2006-08-02 | 2009-09-02 | Ariad Pharma Inc | COMBINATION THERAPY |
| US7288622B1 (en) | 2006-09-19 | 2007-10-30 | Issar Pharmaceuticals Pvt Ltd | Composition for treatment of burns and wounds |
| US7803755B2 (en) | 2006-12-21 | 2010-09-28 | Jesse Jaynes | Molecules for the treatment and prevention of fungal diseases |
| ES2633453T3 (es) | 2008-01-24 | 2017-09-21 | Esperance Pharmaceuticals | Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos |
| CN102076717B (zh) * | 2008-04-30 | 2016-02-03 | 伊缪诺金公司 | 交联剂和它们的用途 |
| WO2011031477A2 (en) * | 2009-08-25 | 2011-03-17 | Esperance Pharmaceuticals, Inc. | Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same |
| AU2010291835A1 (en) * | 2009-09-03 | 2012-04-19 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
| US10093961B2 (en) | 2009-12-22 | 2018-10-09 | Esperance Pharmaceuticals | Methods for diagnosis of and predicting treatment efficacy of hormone receptor expressing tumors, cancers and neoplasias |
| US9586996B2 (en) | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| WO2012050892A2 (en) | 2010-09-29 | 2012-04-19 | Esperance Pharmaceuticals, Inc. | Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors |
| KR20210090298A (ko) | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| CN105073779A (zh) | 2012-11-15 | 2015-11-18 | 埃斯佩兰斯医药公司 | 促卵泡激素(fsh)/裂解结构域融合构建体与其制备和使用的方法 |
-
2013
- 2013-10-30 KR KR1020217021848A patent/KR20210090298A/ko not_active Ceased
- 2013-10-30 CN CN201380069036.9A patent/CN105121472A/zh active Pending
- 2013-10-30 AU AU2013337926A patent/AU2013337926B2/en not_active Ceased
- 2013-10-30 US US14/067,819 patent/US9492563B2/en active Active
- 2013-10-30 KR KR1020157014177A patent/KR102460297B1/ko active Active
- 2013-10-30 BR BR112015009752A patent/BR112015009752A2/pt not_active Application Discontinuation
- 2013-10-30 WO PCT/US2013/067621 patent/WO2014070957A1/en not_active Ceased
- 2013-10-30 CA CA2889475A patent/CA2889475A1/en active Pending
- 2013-10-30 JP JP2015539954A patent/JP6559066B2/ja not_active Expired - Fee Related
- 2013-10-30 EP EP21212744.3A patent/EP4035685A1/en not_active Withdrawn
- 2013-10-30 EP EP13850731.4A patent/EP2914633B1/en active Active
- 2013-10-30 IL IL238323A patent/IL238323B2/en unknown
- 2013-10-30 DK DK13850731.4T patent/DK2914633T3/da active
-
2016
- 2016-11-14 US US15/350,924 patent/US10233214B2/en active Active
-
2018
- 2018-03-21 AU AU2018201996A patent/AU2018201996B2/en not_active Ceased
-
2019
- 2019-01-11 US US16/246,189 patent/US20190367558A1/en not_active Abandoned
-
2021
- 2021-10-15 US US17/503,127 patent/US20220048951A1/en not_active Abandoned
-
2024
- 2024-04-08 US US18/629,543 patent/US20250092092A1/en active Pending